July is Sarcoma Awareness month and we are delighted to say that our very own Jayne Bressington has been nominated for a Just Giving Award.  Jayne has done outstanding work in raising awareness of GIST and PAWS-GISTs in particular and in raising funds.  You can find out more and how to vote on the PAWS-GIST […]

GIST Cancer UK  is partnering again this year with Sarcoma UK on their Open Grant Round 2024. We are interested in supporting research applications that: Target the unmet needs of Paediatric, Adolescent, Wild-Type and Syndromic (PAWS) GIST patients, including: improving our understanding of these subtypes developing novel therapeutic strategies and treatments Researchers can find further […]

We are delighted to announce that the National GIST guidelines have been updated by the British Sarcoma Group GIST specialists and published on 4th June 2024. A copy of the latest guidelines can be viewed and downloaded from here

The fascinating and informative sessions from the recent Cardiff conference can now be viewed at the Patient Meetings section of the website.

Our spring newsletter is now out with information on what’s going on in the GIST world – Register with us if you want to make sure that you receive this on a regular basis.

Some GISTS develop resistance to standard drug treatment (e.g. imatinib, sunitinib, regorafenib, ripritinib).  A new drug is being trialed to prevent the emergence of sub-clones or to treat TKI resistant GISTs.  This trial is being coordinated by Professor Robin Jones at the Royal Marsden Hospital in London.

The PEAK trial is now open at various UK centres and may be relevant for those for whom imatinib is not working.  You can access further details from the clinical trials section of this site.

The GCUK Board would like to extend their appreciation to everyone for their work during the past year in supporting the charity, fellow patients and family, and wish you a merry festive season and best wishes for 2024.

Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors (GIST), according to research presented at the ESMO Congress 2023.

The Autumn Newsletter has arrived with updates on a range of GIST-related matters.  GIST Cancer UK October Newsletter